Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

[1]  A. Vortmeyer,et al.  Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment , 2015, Cancer Immunology Research.

[2]  H. Kluger,et al.  Clinical trials in melanoma patients with brain metastases , 2015, Pigment cell & melanoma research.

[3]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[4]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[5]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[6]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[7]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[9]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[10]  Andreas Rimner,et al.  Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. , 2014, International journal of radiation oncology, biology, physics.

[11]  A. Vortmeyer,et al.  Radiologic and histologic consequences of radiosurgery for brain tumors , 2014, Journal of Neuro-Oncology.

[12]  H. Kluger,et al.  Advances in therapy for melanoma brain metastases. , 2013, Clinics in dermatology.

[13]  Yi-long Wu,et al.  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Hauschild,et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[15]  M. Robbins,et al.  Radiation-induced cognitive impairment--from bench to bedside. , 2012, Neuro-oncology.

[16]  P. Ascierto,et al.  Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. , 2012, The Lancet. Oncology.

[17]  J. Villano,et al.  Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. , 2012, Neuro-oncology.

[18]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[19]  F. Barlesi,et al.  Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Ariyan,et al.  Melanoma brain metastases: is it time to reassess the bias? , 2011, Current problems in cancer.

[21]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[22]  R. Talamini,et al.  Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. , 2010, Lung cancer.

[23]  A. Sloan,et al.  Diagnosis and treatment of melanoma brain metastasis: a literature review. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[24]  J. Knisely,et al.  Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. , 2008, Journal of neurosurgery.

[25]  D. Kondziolka,et al.  Gamma knife radiosurgery for malignant melanoma brain metastases. , 2006, Clinical neurosurgery.

[26]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[27]  M. McDermott,et al.  Gamma knife radiosurgery for malignant melanoma brain metastases. , 1998, The cancer journal from Scientific American.

[28]  H. Hansen,et al.  Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Gershuny,et al.  Central nervous system lnvolvement in malignant melanoma , 1988 .

[30]  G. Hutchins,et al.  Patterned distribution of metastases from malignant melanoma in humans. , 1983, Cancer research.

[31]  A. Dicker,et al.  On the merits and limitations of whole-brain radiation therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.